Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H20I6N4O8.2C7H17NO5 |
Molecular Weight | 1644.2916 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(=O)CCCCC(=O)NC2=C(I)C(C(=O)NC)=C(I)C(C(O)=O)=C2I)=C(I)C(C(O)=O)=C1I
InChI
InChIKey=HOBKVSAGFBYKRQ-VRWDCWMNSA-N
InChI=1S/C24H20I6N4O8.2C7H17NO5/c1-31-21(37)9-13(25)11(23(39)40)17(29)19(15(9)27)33-7(35)5-3-4-6-8(36)34-20-16(28)10(22(38)32-2)14(26)12(18(20)30)24(41)42;2*1-8-2-4(10)6(12)7(13)5(11)3-9/h3-6H2,1-2H3,(H,31,37)(H,32,38)(H,33,35)(H,34,36)(H,39,40)(H,41,42);2*4-13H,2-3H2,1H3/t;2*4-,5+,6+,7+/m.00/s1
Iocarmic acid is a molecule used in seventies as a contrast media for myelography. Iocarmate meglumine (Dimer-X), a water-soluble salt of iocarmic acid was reported to be safe and best tolerated by central nervous system compared to metrizamide in a double-blind test in patients with symptoms of lumbar and sacral root involvement. In the experimental and clinical studies of Dimer-X used for ventriculography the apparent superiority of Dimer-X over Conray 60 and Angiografin as far as side effects were concerned was demonstrated, but there were no particular differences in the intensities of the ventriculograms obtained. Morphological studies of the ventricles and histological examinations of the ventricular walls 1 month after injections of Dimer-X into the ventricles of dogs showed no abnormalities. In the clinical studies, ventriculography Dimer-X, performed on patients with diseases of the central nervous system, produced ventriculograms of good diagnostic value with no side effects, such as convulsions, apart from mild headache or vomiting in 4 instances. Ventriculography with Dimer-X was carried in 15 infants with myelomeningocele and progressive hydrocephalus. However, as was shown in a number of studies iocarmate produced moderate to severe arachnoiditis from myelography in primates. Early meningitis side effects following lumbar radiculography with iocarmate meglumine were demonstrated.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=2951348 | https://www.ncbi.nlm.nih.gov/pubmed/?term=7353945
Curator's Comment: Known to be CNS penetrant in mouse. Human data not available
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Lumbar myelography with meglumine iocarmate and metrizamide. | 1975 May |
|
Solute excretion during intravenous urography. A comparison of sodium iothalamate and sodium iocarmate (iothalamate dimer). | 1975 Nov-Dec |
|
Ventriculography with methylglucamine iocarmate (Dimer-X). Experimental and clinical study. | 1976 |
|
Ionic composition and cardiotoxicity of dimeric contrast media at injection into the coronary arteries of rabbits. | 1976 Jul |
|
A clinical and experimental study of meglumine iocarmate in the subarachnoid space: a complication of positive contrast ventriculography. | 1976 Mar |
|
Water-soluble contrast radiculography of the lumbar region. | 1976 Sep |
|
Arachnoiditis following myelography with water-soluble agents. The role of contrast medium osmolality. | 1977 Dec |
|
Experimental production of arachnoiditis with water-soluble myelographic media. | 1977 Jun |
|
The effect of hydration on the acute and chronic complications of aqueous myelography. An experimental study. | 1978 Dec |
|
Severity of postmyelographic arachnoiditis and concentration of meglumine locarmate in primates. | 1978 Feb |
|
Positive ventriculography using water-soluble contrast media in infants with myelomeningocele and hydrocephalus. | 1978 Feb |
|
The risk of arachnoiditis from experimental nonionic contrast media. | 1980 Aug |
|
Toxicity of X-ray contrast media in cell cultures. | 1980 Jan-Feb |
|
Arachnoiditis from myelography with iopamidol, metrizamide, and iocarmate compared in the animal model. | 1980 Nov-Dec |
|
In vitro testing for the risk of arachnoiditis from myelographic contrast media. | 1985 Aug |
|
Brain beta-endorphin and spinal-cord enkephalin concentrations in experimental arachnoiditis. | 1987 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1085093
1-5 ml Dimer-X (Iocarmic acid salt meglumine iocarmate) administered in patients aged 8 months to 62 years with diseases of the central nervous system
Route of Administration:
Intracoronary
The effect of contrast media on protein and collagen production by fibroblasts in vitro was studied. Iocarmate added to the culture medium caused cells to produce more protein and collagen. The degree to which the contrast medium stimulated collagen production correlated with the risk of arachnoiditis from the intrathecal use of the contrast medium. Iocarmate was toxic to neurons in the concentration of 50 mmol/l and showed variable glial toxicity.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C75625
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
DBSALT002904
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
DTXSID101009319
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
100000077374
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
m6323
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | Merck Index | ||
|
23620992
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
C025504
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
SUB14236MIG
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
54605-45-7
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106389
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
2303MD51O1
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY | |||
|
259-252-7
Created by
admin on Fri Dec 15 16:21:10 GMT 2023 , Edited by admin on Fri Dec 15 16:21:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD